$1.16 Billion is the total value of Boxer Capital, LLC's 37 reported holdings in Q2 2019. The portfolio turnover from Q1 2019 to Q2 2019 was 69.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MRTX | MIRATI THERAPEUTICS INC | $176,703,000 | +40.5% | 1,715,560 | 0.0% | 15.19% | +4.5% | |
| ODT | Buy | ODONATE THERAPEUTICS INC | $123,402,000 | +87.4% | 3,363,377 | +12.9% | 10.61% | +39.3% |
| BGNE | BEIGENE LTDsponsored adr | $111,555,000 | -6.1% | 900,000 | 0.0% | 9.59% | -30.2% | |
| IMMU | Buy | IMMUNOMEDICS INC | $91,084,000 | +15.6% | 6,567,000 | +60.2% | 7.83% | -14.0% |
| ONCE | New | SPARK THERAPEUTICS INC | $61,428,000 | – | 600,000 | +100.0% | 5.28% | – |
| QURE | Sell | UNIQURE NV | $48,094,000 | -15.1% | 615,400 | -35.2% | 4.14% | -36.9% |
| ESPR | ESPERION THERAPEUTICS INC NE | $45,357,000 | +15.9% | 975,000 | 0.0% | 3.90% | -13.9% | |
| PTCT | PTC THERAPEUTICS INC | $45,000,000 | +19.6% | 1,000,000 | 0.0% | 3.87% | -11.1% | |
| DBVT | Buy | DBV TECHNOLOGIES S Asponsored adr | $43,566,000 | +34.5% | 5,300,000 | +26.2% | 3.74% | 0.0% |
| GOSS | GOSSAMER BIO INC | $41,588,000 | +2.4% | 1,875,000 | 0.0% | 3.58% | -23.9% | |
| BCEL | New | ATRECA INC | $32,661,000 | – | 1,733,583 | +100.0% | 2.81% | – |
| MIST | New | MILESTONE PHARMACEUTICALS IN | $29,925,000 | – | 1,102,194 | +100.0% | 2.57% | – |
| FOLD | New | AMICUS THERAPEUTICS INC | $29,016,000 | – | 2,325,000 | +100.0% | 2.50% | – |
| ARGX | New | ARGENX SEsponsored adr | $28,316,000 | – | 200,000 | +100.0% | 2.43% | – |
| MDCO | Buy | MEDICINES CO | $27,353,000 | +63.1% | 750,000 | +25.0% | 2.35% | +21.3% |
| WVE | WAVE LIFE SCIENCES LTD | $26,090,000 | -32.8% | 1,000,000 | 0.0% | 2.24% | -50.1% | |
| RCKT | ROCKET PHARMACEUTICALS INC | $21,991,000 | -14.5% | 1,466,051 | 0.0% | 1.89% | -36.4% | |
| ALLK | Sell | ALLAKOS INC | $20,582,000 | -36.4% | 475,000 | -40.6% | 1.77% | -52.7% |
| SLDB | SOLID BIOSCIENCES INC | $19,971,000 | -37.5% | 3,473,272 | 0.0% | 1.72% | -53.5% | |
| KURA | KURA ONCOLOGY INC | $16,634,000 | +18.7% | 844,789 | 0.0% | 1.43% | -11.8% | |
| PRVL | New | PREVAIL THERAPEUTICS INC | $14,825,000 | – | 1,123,105 | +100.0% | 1.28% | – |
| GBT | GLOBAL BLOOD THERAPEUTICS IN | $13,150,000 | -0.6% | 250,000 | 0.0% | 1.13% | -26.1% | |
| New | ESPERION THERAPEUTICS INC NEcall | $11,630,000 | – | 250,000 | +100.0% | 1.00% | – | |
| CBAY | CYMABAY THERAPEUTICS INC | $8,950,000 | -46.1% | 1,250,000 | 0.0% | 0.77% | -59.9% | |
| MTNB | MATINAS BIOPHARMA HLDGS INC | $8,727,000 | -21.4% | 10,188,312 | 0.0% | 0.75% | -41.6% | |
| MRSN | New | MERSANA THERAPEUTICS INC | $8,440,000 | – | 2,084,000 | +100.0% | 0.73% | – |
| New | IMMUNOMEDICS INCcall | $8,322,000 | – | 600,000 | +100.0% | 0.72% | – | |
| IDYA | New | IDEAYA BIOSCIENCES INC | $7,612,000 | – | 764,252 | +100.0% | 0.65% | – |
| AKRO | New | AKERO THERAPEUTICS INC | $7,597,000 | – | 396,695 | +100.0% | 0.65% | – |
| KDMN | New | KADMON HLDGS INC | $7,597,000 | – | 3,688,100 | +100.0% | 0.65% | – |
| MEIP | MEI PHARMA INC | $7,283,000 | -18.6% | 2,913,091 | 0.0% | 0.63% | -39.5% | |
| LJPC | New | LA JOLLA PHARMACEUTICAL CO | $5,319,000 | – | 575,000 | +100.0% | 0.46% | – |
| KALV | KALVISTA PHARMACEUTICALS INC | $4,430,000 | -22.6% | 200,000 | 0.0% | 0.38% | -42.4% | |
| KNSA | KINIKSA PHARMACEUTICALS LTD | $3,934,000 | -25.0% | 290,577 | 0.0% | 0.34% | -44.3% | |
| VYGR | New | VOYAGER THERAPEUTICS INC | $2,722,000 | – | 100,000 | +100.0% | 0.23% | – |
| CLRB | New | CELLECTAR BIOSCIENCES INC | $2,006,000 | – | 920,000 | +100.0% | 0.17% | – |
| NVUS | NOVUS THERAPEUTICS INC | $328,000 | -74.8% | 324,383 | 0.0% | 0.03% | -81.5% | |
| BIIB | Exit | BIOGEN INC | $0 | – | -200,000 | -100.0% | -5.47% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MIRATI THERAPEUTICS INC | 32 | Q3 2023 | 55.2% |
| BEIGENE LTD | 31 | Q3 2023 | 15.6% |
| KURA ONCOLOGY INC. | 24 | Q3 2021 | 4.7% |
| ROCKET PHARMACEUTICALS INC | 23 | Q3 2023 | 5.4% |
| DBV TECHNOLOGIES S A | 23 | Q3 2023 | 3.9% |
| MEI PHARMA INC | 21 | Q2 2023 | 1.4% |
| SYNDAX PHARMACEUTICALS INC | 20 | Q3 2021 | 3.1% |
| GOSSAMER BIO INC | 19 | Q3 2023 | 4.7% |
| ODONATE THERAPEUTICS INC | 18 | Q1 2022 | 12.5% |
| ESPERION THERAPEUTICS INC NE | 18 | Q2 2021 | 11.0% |
View Boxer Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| IDEAYA Biosciences, Inc. | February 14, 2023 | 2,202,812 | 4.6% |
| Milestone Pharmaceuticals Inc. | February 14, 2023 | 698,861 | 2.0% |
| SpringWorks Therapeutics, Inc. | September 19, 2022 | 3,421,541 | 5.7% |
| iTeos Therapeutics, Inc. | May 11, 2022 | 2,154,058 | 6.1% |
| Atreca, Inc. | February 14, 2022 | 2,202,333 | 7.2% |
| Biomea Fusion, Inc. | February 14, 2022 | 1,188,405 | 4.1% |
| Cabaletta Bio, Inc. | February 14, 2022 | 540,000 | 1.9% |
| CymaBay Therapeutics, Inc. | February 14, 2022 | ? | ? |
| DBV Technologies S.A. | February 14, 2022 | 1,067,299 | 1.9% |
| Elevation Oncology, Inc. | February 14, 2022 | 872,780 | 3.8% |
View Boxer Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-12 |
| 4 | 2024-02-08 |
| SC 13D/A | 2024-02-08 |
| 4 | 2024-01-25 |
| SC 13D/A | 2024-01-25 |
| SC 13G | 2024-01-18 |
| SC 13D/A | 2023-12-18 |
View Boxer Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.